Table 1 Pharmacokinetic parameters of baicalin and geniposide in CG and MG rats after intravenous administration of QKLI.

From: An integrated strategy by using target tissue metabolomics biomarkers as pharmacodynamic surrogate indices to screen antipyretic components of Qingkaikling injection

Pharmacokinetic parameters

Baicalin

Geniposide

CG

MG

CG

MG

t1/2 (h)

2.131 ± 1.389

1.541 ± 0.903

1.510 ± 1.510

1.229 ± 0.665

tmax (h)

0.5

0.5

0.5

0.5

Cmax (ng/mL)

97.372 ± 20.081

215.313 ± 74.120**

50.348 ± 23.899

70.081 ± 24.863*

AUC0-t (h·ng/mL)

83.114 ± 30.364

195.187 ± 73.973**

42.553 ± 30.721

70.324 ± 30.291*

AUC0-∞ (h·ng/mL)

89.644 ± 39.257

212.450 ± 102.092**

45.019 ± 36.711

72.959 ± 30.230*

MRT0-t (h)

0.979 ± 0.136

1.047 ± 0.307

0.894 ± 0.123

1.125 ± 0.253

MRT0-∞ (h)

1.449 ± 0.616

1.434 ± 0.968

1.131 ± 0.534

1.363 ± 0.420

  1. *p < 0.05, **p < 0.01, compared with CG rats.